Home/Filings/4/0000950170-25-005882
4//SEC Filing

Aker Christopher Ray 4

Accession 0000950170-25-005882

CIK 0001505512other

Filed

Jan 14, 7:00 PM ET

Accepted

Jan 15, 5:00 PM ET

Size

6.9 KB

Accession

0000950170-25-005882

Insider Transaction Report

Form 4
Period: 2025-01-13
Aker Christopher Ray
Sr. VP & General Counsel
Transactions
  • Sale

    Common Stock

    2025-01-13$1.26/sh38,547$48,69354,634 total
  • Sale

    Common Stock

    2025-01-14$1.26/sh5,088$6,42749,546 total
Footnotes (2)
  • [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) which commenced vesting on January 9, 2025. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.
  • [F2]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) which commenced vesting on January 12, 2024. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.

Documents

1 file

Issuer

Regulus Therapeutics Inc.

CIK 0001505512

Entity typeother

Related Parties

1
  • filerCIK 0001762611

Filing Metadata

Form type
4
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 5:00 PM ET
Size
6.9 KB